Karyopharm Therapeutics Inc (OQ:KPTI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 85 Wells Ave
NEWTON CENTER MA 02459-3298
Tel: N/A
Website: https://karyopharm.com
IR: See website
<
Key People
Richard A. Paulson
President, Chief Executive Officer, Director
Michael P. Mason
Chief Financial Officer, Executive Vice President, Treasurer
Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Stuart Poulton
Executive Vice President, Chief Development Officer
Michael Mano
Senior Vice President, General Counsel, Secretary
 
Business Overview
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company's product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Financial Overview
For the fiscal year ended 31 December 2023, Karyopharm Therapeutics Inc revenues decreased 7% to $146M. Net loss decreased 13% to $143.1M. Revenues reflect Product revenue, net decrease of 7% to $112M, License and other revenue decrease of 7% to $34M. Lower net loss reflects Pharmaceutical segment loss decrease of 9% to $129.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.02 to -$1.25.
Employees: 325 as of Feb 23, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $285.71M as of Dec 31, 2023
Annual revenue (TTM): $146.03M as of Dec 31, 2023
EBITDA (TTM): -$129.01M as of Dec 31, 2023
Net annual income (TTM): -$143.10M as of Dec 31, 2023
Free cash flow (TTM): -$92.72M as of Dec 31, 2023
Net Debt Last Fiscal Year: $111.96M as of Dec 31, 2023
Shares outstanding: 115,067,083 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.